Press Releases Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
10.48 ^USD	-4.81%		-21.32%	-53.83%

Mar. 22	HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating	MT
Mar. 21	Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 21	GL
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	Mar. 20	GL
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	Mar. 20	AQ
Cabaletta Bio to Participate in Upcoming Investor Conferences in March	Feb. 27	GL
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis	Feb. 01	GL
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Jan. 31	GL
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis	Jan. 08	GL
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis	Jan. 08	AQ
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 02	GL
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference	Nov. 28	GL
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 09	GL
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform	Nov. 06	BU
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis	Nov. 06	GL
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November	23-10-30	GL
Cabaletta Bio : Corporate Presentation	23-10-02	PU
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201	23-10-02	GL
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201	23-10-02	AQ
Cabaletta Bio to Participate in Upcoming Investor Conferences in September	23-09-19	GL
Cabaletta Bio : Corporate Presentation	23-09-05	PU
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September	23-08-30	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Press Releases

Filters